How would you treat a patient with TNBC with a residual strongly PR+, ER- breast mass on mastectomy after neoadjuvant KEYNOTE 522 based chemoimmunotherapy?

Would you consider using endocrine therapy, pembrolizumab, capecitabine, or CDK 4/6 inhibitor?

Answer from: Medical Oncologist at Academic Institution

I would treat such a patient the same way that I would any patient with residual TNBC after neoadjuvant chemotherapy and pembrolizumab, which depends to some extent upon the patient's stage at diagnosis and the extent of residual disease at surgery - in patients with residual disease after neoadjuva...

Comments

Medical Oncologist at Colorado Permanente Medical Group Hematology & Oncology
On a similar note, I just saw a woman post op who ...

Medical Oncologist at Warren Alpert Medical School of Brown University
The low PR expression wouldn't dissuade me from tr...

Medical Oncologist at NYU Winthrop Hospital
I respectfully disagree: The patient is PR positiv...

Medical Oncologist at Missouri Cancer Associates
I think that any hormone sensitivity is important....

Medical Oncologist at Northwest Medical Specialties PLLC
Would recommend both Adjuvant Pembro and Hormone b...

Medical Oncologist at Northwest Medical Specialties PLLC
Edit: Hormone blocking therapy recommended fo...

Please select the option that best describes you:

How would you treat a patient with TNBC with a residual strongly PR+, ER- breast mass on mastectomy after neoadjuvant KEYNOTE 522 based chemoimmunotherapy?

Related Questions